Advertisement

Topics

Cytokinetics Company Profile

16:36 EDT 25th September 2017 | BioPortfolio

Cytokinetics is focused on the complementary missions of drug discovery and the commercialization of novel cellular bioinformatics technologies. Cytokinetics drug discovery programs are exploiting the field of cytoskeletal pharmacology for the identification of entirely novel classes of therapeutic compounds. Cytokinetics cellular bioinformatics technologies, called Cytometrix™, are designed to increase the productivity and accelerate the speed of pharmaceutical discovery and development. Synergies generated by these two program areas have allowed Cytokinetics to move at a rapid pace toward the characterization of novel small molecule therapeutics.

Location

280 East Grand Avenue, Suite #2
South San Francisco
CA
94080
United States of America

Contact

Phone: 650 624 3000
Fax: 650 624 3010
Email: hr@cytokinetics.com


News Articles [32 Associated News Articles listed on BioPortfolio]

Funding round brings in $75M for Cytokinetics

A follow-on offering has raised $75 million for Cytokinetics.  -More- 

'Writing on the wall' suggests progress in ALS may be imminent, says Cytokinetics CEO

San Franciscan firm Cytokinetics is pursuing an unusual angle to therapeutic discovery, starting from…

'Handwriting on the wall' suggests progress in ALS may be imminent, says Cytokinetics CEO

San Franciscan firm Cytokinetics is pursuing an unusual angle to therapeutic discovery, starting from…

Cytokinetics nets $72mm via FOPO

Cytokinetics Inc. (developing muscle activators) netted $72mm through the follow-on public offering of 5.26mm shares $14.25 each.

Cytokinetics evaluates CK-2127107 in Phase II trial to treat ALS

US-based Cytokinetics has started a Phase II FORTITUDE-ALS clinical trial of CK-2127107 for the treatment of patients with amyotrophic lateral sclerosis (ALS).

Cytokinetics receives FDA orphan drug status for Ck-2127107 to treat SMA

Biopharmaceutical company Cytokinetics’ CK-2127107 has received orphan drug designation from the Office of Orphan Products Development of the US Food and Drug Administration (FDA) for the potential ...

Cytokinetics begins dosing omecamtiv mecarbil in Phase III cardiovascular trial

Cytokinetics has begun dosing patients in Japan in a Phase III cardiovascular outcomes clinical trial (GALACTIC-HF) of omecamtiv mecarbil as a potential heart failure treatment.

Cytokinetics raises $75M follow-on

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [1 Associated Clinical Trials listed on BioPortfolio]

A Study of SB-743921 in Non-Hodgkin's Lymphoma

Cytokinetics' CY 2121 Study is an early-phase trial arranged into two phases. The objectives of the first phase of the study are to assess the safety, tolerability and to identify the max...

Companies [0 Results]

None

More Information about "Cytokinetics" on BioPortfolio

We have published hundreds of Cytokinetics news stories on BioPortfolio along with dozens of Cytokinetics Clinical Trials and PubMed Articles about Cytokinetics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Cytokinetics Companies in our database. You can also find out about relevant Cytokinetics Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...


Corporate Database Quicklinks



Searches Linking to this Company Record